Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial have?
Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial has 64 citations in the OpenAlex counts ScholarIQ stores.
When was Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial published?
Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial has 2012 year in the ScholarIQ index.
What is the open-access status of Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial?
Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial has gold oa status in the ScholarIQ index.
What is the DOI of Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial?
The DOI for Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial is on the source record.
What is the PMID of Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial?
The PMID for Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial is on the source record.
What is the OpenAlex record for Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial?
The OpenAlex for Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial is on the source record.